<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CEFTAZIDIME</span><br/>(sef'tay-zi-deem)<br/><span class="topboxtradename">Fortaz, </span><span class="topboxtradename">Tazicef, </span><span class="topboxtradename">Tazidime<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">third-generation cephalosporin</span><br/><b>Prototype: </b>Cefotaxime sodium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg, 1 g, 2 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic, third-generation broad-spectrum cephalosporin antibiotic similar to cefotaxime but more active against <i>Pseudomonas aeruginosa</i> and less active against <i>Staphylococci</i> and <i>Bacteroides fragilis</i>. Preferentially binds to one or more of the penicillin-binding proteins (PBP) located on cell walls of susceptible microbes;
         this inhibits third and final stage of bacterial cell wall synthesis, leading to cell death of the bacterium.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effectively treats bone and joint infections, gynecologic and gram negative infections, meningitis, intra-abdominal infections,
         septicemia, and respiratory tract, urinary tract, and skin and soft tissue infections, by reducing or eliminating the infection.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To treat infections of lower respiratory tract, skin and skin structures, urinary tract, bones and joints; also used to treat
         bacteremia, gynecological, intra-abdominal and CNS infections (including meningitis).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Surgical prophylaxis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cephalosporins and related beta-lactam antibiotics; pregnancy (category B).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 12 g q812h, up to 2 g q6h<br/><span class="rdage">Geriatric:</span> <span class="rdroute">IV/IM</span> 12 g q12h<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span>
<i>, 30 mg/kg q12h; <i>1 mo12 y</i>, 3050 mg/kg/d in 3 divided doses (max: 6 g/d)<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute by adding 3 mL sterile water or bacteriostatic water for injection or 0.5% or 1% lidocaine HCl injection
            to 1 g vial to yield 280 mg/mL.
         </li>
<li>Inject into large muscle mass (e.g., upper outer quadrant of gluteus maximus or lateral part of thigh).</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Add 10 mL of sterile water for injection to 1 g to yield 280 mg/mL.  <span class="methodtype">Intermittent:</span> Further dilute with 50100 mL of D5W, NS, or RL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over 35 min.  <span class="methodtype">Intermittent:</span> Give over 3060 min. If given through a Y-type set, discontinue other solutions during infusion of ceftazidime.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<span class="classification">aminoglycosides</span>, <b>aminophylline,</b>
<b>ranidine.</b>
<span class="incompattype">Y-site:</span>
<span class="classification">Amiodarone, aminoglycosides</span>, <b>amphotericin B cholesteryl complex,</b>
<b>amsacrine,</b>
<b>azithromycin, doxorubicin liposome,</b>
<b>fluconazole,</b>
<b>idarubicin,</b>
<b>midazolam,</b>
<b>pentamidine,</b>
<b>sargramostim,</b>
<b>vancomycin,</b>
<b>warfarin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Protect sterile powder from light. Reconstituted solution is stable 7 d when refrigerated at 4°5° C (39°41°
            F); for 1824 h when stored at 15°30° C (59°86° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever, phlebitis, pain or inflammation at injection site, superinfections. <span class="typehead">GI:</span> Nausea, vomiting, <span class="speceff-common">diarrhea,</span> abdominal pain, metallic taste, drug-associated <span class="speceff-life">pseudomembranous colitis</span>. <span class="typehead">Skin:</span> Pruritus, rash, urticaria. <span class="typehead">Urogenital:</span> Vaginitis, candidiasis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>False-positive reactions for <span class="alt">urine glucose</span> have been reported using <span class="alt">copper sulfate</span> (e.g., <span class="alt">Benedict's solution,</span>
<span class="alt">Clinitest</span>). <span class="alt">Glucose oxidase tests (Clinistix, TesTape)</span> are unaffected. May cause positive <span class="alt">direct antiglobulin (Coombs') test</span> results, which can interfere with <span class="alt">hematologic studies</span> and <span class="alt">transfusion cross-matching procedures.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid</b> decreases renal elimination of ceftazidine. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 1 h after IM or IV. <span class="typehead">Distribution:</span> CNS penetration with inflamed meninges; also penetrates bone, gallbladder, bile, endometrium, heart, skin, and ascitic and
      pleural fluids; crosses placenta. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> 8090% excreted unchanged in urine in 24 h; small amount excreted in breast milk. <span class="typehead">Half-Life:</span> 2560 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine history of hypersensitivity to cephalosporins and penicillins, and other drug allergies, before therapy begins.</li>
<li>Lab tests: Perform culture and sensitivity studies before initiation of therapy and during therapy as indicated. Therapy may
            begin pending test results.
         </li>
<li>If administered concomitantly with another antibiotic, monitor renal function and report if symptoms of dysfunction appear
            (e.g., changes in I&amp;O ratio and pattern, dysuria).
         </li>
<li>Be alert to onset of rash, itching, and dyspnea. Check patient's temperature. If it is elevated, suspect onset of hypersensitivity
            reaction (see Appendix F).
         </li>
<li>Monitor for superinfection. (See Appendix F.)</li>
<li>If diarrhea occurs and is severe, suspect pseudomembranous colitis (caused by <i>Clostridium difficile</i>). Check temperature: Report fever and severe diarrhea to physician; drug should be discontinued.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report loose stools or diarrhea promptly.</li>
<li>Report any signs or symptoms of superinfection promptly (see Appendix F).</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>